Results 41 to 50 of about 39,632 (214)

COVID‐19 in a human T‐cell lymphotropic virus type‐1 carrier

Clinical Case Reports, 2022
This is the first report of COVID‐19 in a human T‐cell lymphotropic virus type‐1 (HTLV‐1) carrier. HTLV‐1 infection can cause immune dysfunction even in asymptomatic carriers.
Takatoshi Enomoto, Takayuki Shiroyama, Haruhiko Hirata, Saori Amiya, Yuichi Adachi, Takayuki Niitsu, Yoshimi Noda, Reina Hara, Kiyoharu Fukushima, Yasuhiko Suga, Kotaro Miyake, Shohei Koyama, Kota Iwahori, Izumi Nagatomo, Natsuko Tokuhira, Akinori Uchiyama, Yoshito Takeda, Atsushi Kumanogoh   +17 more
doaj   +1 more source

Human T-lymphotropic virus and transfusion safety. Does one size fit all? [PDF]

, 2015
Human T-cell leukemia viruses (HTLV-1 and HTLV-2) are associated with a variety of human diseases, including some severe ones. Transfusion transmission of HTLV through cellular blood components is undeniable.
Catalano, Liviana, Facco, Giuseppina, Grazzini, Giuliano, Liumbruno, Giancarlo Maria, Marano, Giuseppe, Piccinini, Vanessa, Pupella, Simonetta, VAGLIO, Stefania   +7 more
core   +1 more source

The tax-inducible actin-bundling protein fascin is crucial for release and cell-to-cell transmission of human T-cell leukemia virus type 1 (HTLV-1) [PDF]

, 2016
The delta-retrovirus Human T-cell leukemia virus type 1 (HTLV-1) preferentially infects CD4(+) T-cells via cell-to-cell transmission. Viruses are transmitted by polarized budding and by transfer of viral biofilms at the virological synapse (VS ...
Gettemans, Jan, Gross, Christine, Kalmer, Martina, Millen, Sebastian, Thoma-Kress, Andrea K, Wiesmann, Veit, Wittenberg, Thomas   +6 more
core   +6 more sources

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

Advanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun, Haochen Yang, Qing Xu, Xingya Li, Jinxing Lou, Jianchun Duan, Jiachen Xu, Zhuqing Liu, Yong Xia, Zhicai Lin, Linlin Li, Dan Sun, Jiaguo Li, Tao Liu, Jun Guo, Wenfeng Xu, Weimin Zhu, Yi Liu, Boyang Sun, Jia Zhong, Lijie Rong, Qijun Qian, Chenqi Xu, Jie Wang   +23 more
wiley   +1 more source

Dynamics of perinatal bovine leukemia virus infection [PDF]

, 2014
BACKGROUND: Bovine leukemia virus (BLV) is highly endemic in many countries, including Argentina. As prevention of the spread from infected animals is of primary importance in breaking the cycle of BLV transmission, it is important to know the ...
Alvarez, Irene, Gutiérrez, Gerónimo, Merlini, Ramiro, Rondelli, Flavia, Trono, Karina Gabriela   +4 more
core   +3 more sources

Seroprevalence of Human T-cell Lymphotropic Virus Types I/II Among Blood Donors in a Tertiary Hospital in Oman

Oman Medical Journal
Objectives: Routine blood donor screening of human T-cell lymphotropic virus (HTLV) has been practiced in Oman since 2017. Limited data exists on HTLV seroprevalence among Omanis.
Noora Al-Bulushi, Khuloud Al Maamari, Fatma Ba Alawi, Arwa Z. Al-Riyami, Ali Al Marhoobi   +4 more
doaj   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source

Cryo-EM structure of the deltaretroviral intasome in complex with the PP2A regulatory subunit B56γ

Nature Communications, 2020
Human T-cell lymphotropic virus type 1 (HTLV-1) is a pathogenic deltaretrovirus. Here the authors resolve the cryo-EM structure of the deltaretroviral intasome in complex with the human host PP2A regulatory subunit.
Michał S. Barski, Jordan J. Minnell, Zuzana Hodakova, Valerie E. Pye, Andrea Nans, Peter Cherepanov, Goedele N. Maertens   +6 more
doaj   +1 more source

Structural basis for the inhibition of HTLV-1 integration inferred from cryo-EM deltaretroviral intasome structures

Nature Communications, 2021
Human T-cell lymphotropic virus type 1 (HTLV-1) is an oncogenic deltaretrovirus. Here the authors provide structural characterization of the binding mechanism of novel integrase strand transfer inhibitor (INSTI) candidates to limit HTLV-1 infection.
Michal S. Barski, Teresa Vanzo, Xue Zhi Zhao, Steven J. Smith, Allison Ballandras-Colas, Nora B. Cronin, Valerie E. Pye, Stephen H. Hughes, Terrence R. Burke, Peter Cherepanov, Goedele N. Maertens   +10 more
doaj   +1 more source

Human T-Lymphotropic virus type 1 and human immunodeficiency virus co-infection in rural Gabon.

PLoS ONE, 2022
IntroductionHuman T-cell lymphotrophic virus type-1 (HTLV-1) and human immunodeficiency virus (HIV-1) co-infection occur in many populations. People living with HIV-1 and infected with HTLV-1 seem more likely to progress rapidly towards AIDS. Both HTLV-1
Augustin Mouinga-Ondémé, Larson Boundenga, Ingrid Précilya Koumba Koumba, Antony Idam Mamimandjiami, Abdoulaye Diané, Jéordy Dimitri Engone-Ondo, Delia Doreen Djuicy, Jeanne Sica, Landry Erik Mombo, Antoine Gessain, Avelin Aghokeng Fobang   +10 more
doaj   +1 more source